Lilly closes $6.3B ImClone acquisition

IBJ Staff
November 24, 2008
Back to TopCommentsE-mailPrintBookmark and Share
Indianapolis-based Eli Lilly and Co. said today that it has closed its acquisition of ImClone Systems Inc., a New York-based developer of cancer drugs.

Lilly paid $70 in cash for each share of ImClone in a deal worth about $6.3 billion.

Lilly outbid New York rival Bristol-Myers Squibb Co., but analysts question whether Lilly will make enough money from the cancer drugs to make the expensive acquisition profitable.

Post a comment to this story

We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
You are legally responsible for what you post and your anonymity is not guaranteed.
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
Subscribe to IBJ